DEA to Hold Hearing on Psychedelic Ban

The U.S. Drug Enforcement Administration (DEA) has announced a hearing over its recent proposal to place five tryptamine hallucinogens in schedule I of the Controlled Substances Act. The initial proposal, published in a Notice of Proposed Rulemaking published in the Federal Register, caused an outcry among scientists who said it would hamper ongoing research efforts.

The proposal would affect 4-Hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT); 5-Methoxy-alphamethyltryptamine (5-MeO-AMT); N-Isopropyl-5-Methoxy-N-Methyltryptamine (5-MeO-MiPT); N,N-Diethyl-5-methoxytryptamine (5-MeO-DET); and N,N-Diisopropyltryptamine (DiPT).

“The proposal in the NPRM to place these substances in schedule I was based primarily on the scientific and medical evaluations and recommendations provided by the Department of Health and Human Services (HHS) to DEA,” the agency said. “In those submissions to DEA, HHS concluded that these five substances meet the criteria for placement in schedule I as they all have a high potential for abuse, no currently medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. DEA is bound by the recommendations of HHS as to scientific and medical matters.”

The hearing will take place August 22, 2022 at 9 a.m. ET at the DEA Hearing Facility, 1550 Crystal Drive, Suite 901, Arlington, Virginia 22202. Those who wish to participate must provide written notice before August 5, 2022.

Read more here.